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1. Introduction 
Meningitis is a clinical condition involving inflammation of the meninges that most 
commonly affects otherwise healthy people. Generally, the meningitides are of infectious 
etiology that can be viral, bacterial, fungal, or parasitic in nature, although iatrogenic causes 
are rarely reported (Table 1). Inflammation of the meninges can pose serious dangers to 
patients, given that many of the areas affected are encased by bony structures that can 
exacerbate tissue damage caused by swelling. Collapse of the blood vessels, causing hypoxic 
damage, is a particularly dangerous effect of inflammation in the brain. In fact, permanent 
disability and death may result from all forms of meningitis. Further, sepsis, bacteremia, or 
other disease processes can be caused by the same infectious agents that cause meningitis. 
Epidemics associated with certain pathogens, like the meningococcus, pose a serious public 
health risk, and therefore require prevention and control strategies. The quest to limit the  
 Viruses* Bacteria Fungi 
Vaccine 
preventable 
Japanese and tick-
borne encephalitis 
Polio  
Measles  
Mumps  
Streptococcus pneumoniae
(“Pneumococcus”) 
Neisseria meningitidis serogroups A, 
C, W-135, Y 
Haemophilus influenzae type b 
Tuberculosis 
Vaccines under 
clinical 
investigation 
Group B streptococcus
Neisseria meningitidis serogroup B  
Staphylococcus aureus 
No vaccines 
available 
West Nile 
Herpes simplex 
Neisseria meningitidis serogroup X 
Escherichia coli 
Listeria monocytogenes 
Lyme (Borrelia burgdorferi) 
Candida albicans  
Cryptococcus 
neoformans  
Histoplasma 
*Most commonly enteroviruses, arboviruses, herpes, measles and mumps 
Rarely, meningitis may be caused by parasites or as a side effect of medication. 
Table 1. Examples of pathogens associated with meningitides, encephalitis, or sepsis (2-3) 
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public health impact of meningitis has led to the application of various public health 
strategies, including vaccine campaigns, over the last century (1-2). This chapter places 
meningitis vaccine policy in the context of several forces: public perception and media 
activity, clinical diagnosis and laboratory testing, antibiotic effectiveness and vaccine safety, 
efficacy and cost-effectiveness. Country and situational examples will be given. 
2. Disease factors that impact policy decisions 
The global epidemiology of meningitis changed dramatically during the twentieth century 
as vaccines and antibiotics became available to prevent and treat this deadly disease (4-5). 
The potential public health impact of meningitis-causing organisms is affected by disease 
incidence, severity and scope, case fatality ratio, risk of contagion, rate of disease 
progression and additional acute and chronic disease caused by the pathogen. The 
Meningitis Research Foundation notes that, with the exception of measles and mumps (6) 
which have been vaccine-preventable for decades, the relatively mild severity and generally 
good prognosis associated with the viral meningitides makes for mild concern among 
policymakers (3). The World Health Organization and the Pan American Health 
Organization consider bacterial, particularly meningococcal, meningitis to be among the 
world’s most important public health problems (2).  
 
Fig. 1. Scanning electromicrograph of the pneumococcus. photo by Janice Haney Carr. 
Centers for Disease Control and Prevention Public Health Image Library ID # 265. (15) 
The most common causes of bacterial meningitis in the United States, Europe and many 
other developed countries since the 1980s have been the pneumococcus, Haemophilus 
influenzae type b, the meningococcus, group B streptococcus, and Listeria monocytogenes (4-
5, 7). In Africa, seasonal outbreaks and epidemics of meningococcal meningitis and 
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septicemia numerically represent the greatest public health impact in this context (1, 8-9). 
The three polysaccharide-encapsulated bacteria for which licensed vaccines are widely 
available, the pneumococcus, Haemophilus influenzae type b , and the meningococcal 
serogroups A, C, W-135 and Y, have been the major focus of vaccine development and 
policy efforts (1-2, 10-11). Following the initial introduction of conjugate polysaccharide 
vaccines against these pathogens during the 1980s and 1990s the epidemiology of bacterial 
meningitis has changed dramatically. Further challenges to reducing the global burden of 
meningitis remain, among them the need for vaccines against Group B streptococcus, 
which accounts for a large proportion of newborn and very young infant infections, and 
meningococcal serogroup B (11-12). Indeed, in a recent report, Group B streptococcus was 
responsible for more than 85% of bacterial meningitis among US infants less than 2 
months of age (5). In regions where vaccines against pneumococcus and Haemophilus 
influenzae type b are not available, Group B streptococcus is also an important cause of 
meningitis in the first 3 months of life (13-14).  
The clinical characteristics of various meningitides are discussed in detail in other chapters. 
Risk factors for bacterial meningitis include age (the very young, the elderly, adolescents), 
underlying medical conditions (innate or acquired immunosuppression, complement 
deficiency, shunts, cochlear implants) and lifestyle factors such as poverty, college 
attendance, or travel. Increasing evidence suggests that genetic factors increase the risk of 
contracting bacterial meningitis (Table 2). 
Genetic condition Arising infection 
Severe congenital neutropenia Recurrent infections 
Immunoglobulin deficiency Pneumococcal infection 
Severe combined immune deficiency Recurrent infections 
Complement deficiency Meningococcal infection 
TLR and NEMO Pneumococcal infection 
Mal/TIRAP gene Haemophilus influenzae type b vaccine failure 
TLR: toll-like receptor; NEMO: NF-kappa-B essential modulator; TIRAP: toll-interleukin 1 receptor 
(TIR) domain containing adaptor protein. 
(1, 16-20) 
Table 2. Known genetic predispositions to bacterial meningitis 
Unique risk factors (Table 3) for meningococcal meningitis have been observed in adolescents 
and young adults: close social contact (e.g. bars, discotheques, dormitories), kissing, smoking 
(1, 3, 17-18). For Haemophilus influenzae type b, and pneumococcus, low socioeconomic status 
and ethnic minority group status represent risk factors of special note (5). 
Exposure to antibiotics can increase the risk of infection with an antibiotic-resistant 
organism, as observed for pneumococcal infections, while vaccine policy has exerted a 
downward pressure on antibiotic resistance (26). For newborn Group B streptococcus 
infection, maternal colonization alone is a risk factor – accordingly, some regions 
recommend administration of prophylactic antibiotics during labor and delivery for all 
women known to be colonized (27). 
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Crowding factors 
Moving into a college dormitory, particularly freshmen  
Moving into army barracks, particularly new military recruits 
Travel 
Attendance at the Hajj or Umrah pilgrimages 
Travel to areas with hyperendemic or epidemic disease 
Social factors 
Pub or discotheque attendance 
Kissing 
Smoking and exposure to second-hand smoke 
(1,21-25) 
Table 3. Examples of risk factors for developing meningococcal meningitis 
Rates of asymptomatic carriage may affect the transmission of encapsulated pathogenic 
bacteria and thereby lead to colonization, invasion and invasive disease. The ability to 
adhere to or penetrate the mucosa, or to survive and multiply in blood or infect organs 
(especially the brain) are commonly-recognized virulence factors that, like epidemiology, 
may differ among strains, serogroups or types of encapsulated bacteria within a species (1, 
5, 24, 28-32). Susceptibility to disease or asymptomatic carriage may coincide or occur in 
distinct population groups (Table 4). 
 
Carriage in infants, disease in infants 
Pneumococcal diseases: bacteremia, meningitis, otitis media, pneumonia 
Invasive Haemophilus influenzae type b  disease: bacteremia, meningitis, epiglotitis 
Carriage in adolescents and/or adults, disease in adolescents and/or adults 
Invasive meningococcal meningitis and septicemia in travelers 
Invasive meningococcal meningitis and septicemia in military recruits 
Carriage in adolescents and adults, disease in infants 
Invasive meningococcal meningitis in infants in developed countries 
Maternal colonization with Group B streptococcus, disease in infants 
(1,5, 16, 20, 22-23, 31-32) 
Table 4. Examples of carriage versus invasive disease profiles 
Ideally, definitive laboratory tests would rapidly confirm or exclude bacterial meningitis, 
determine the organism and identify its pattern of antibiotic susceptibility. Unfortunately, 
diagnosis of bacterial meningitis in the absence of a positive culture remains at best 
imprecise, despite numerous algorithms and putative biomarkers (Table 5). A recent early 
diagnostic model relies on dichotomized variables of peripheral blood polymorphonuclear 
cell count >16 × 109/l, serum C-reactive protein >100 mg/l and hemorrhagic rash, with a 
predicted probability of bacterial meningitis or meningococcal septicemia >95% with the 
presence of any one variable and >99% for two or more (33). Serum procalcitonin 
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distinguished viral from bacterial meningitis more effectively than C-reactive protein or 
leukocyte counts (34-35). However, methods must approach 100% sensitivity to avoid 
missed cases. Immediate and urgent administration of antibiotics until the results of 
microbiological tests become available is therefore recommended, (24, 36-37) although this 
practice may hinder diagnostic methods and surveillance that rely on culture. More 
sensitive molecular diagnostic techniques such as polymerase chain reaction (PCR) can 
enable definitive diagnosis in these cases (1, 38). Administration of preemptive antibiotics to 
viral meningitis patients can be costly and may indirectly contribute to antibiotic resistance. 
Suboptimal dosing of preemptive antibiotics may result in penetration into the 
cerebrospinal fluid or across the blood-brain barrier that is inadequate to eradicate bacterial 
pathogens (36-37). 
 
Clinical criteria: hemorrhagic nonblanching rash, neck stiffness, altered mental state, 
shock, hypotension, back rigidity, photophobia, toxic or moribund state, seizures 
headache, vomiting, fever, etc. 
Bacterial antigen testing 
Gram staining 
Blood markers: C-reactive protein level, white blood cell count 
Cerebrospinal fluid markers: protein level, glucose level, white blood cell count, 
neutrophil count 
Cultures of blood or cerebrospinal fluid 
Serum procalcitonin 
Blood polymorphonuclear cell count >16 × 109/l, serum C-reactive protein >100 mg/l 
and/or hemorrhagic rash 
(33-39) 
Table 5. Examples of algorithms and biomarkers for bacterial meningitis. 
Difficulties in differential diagnosis, combined with the severe consequences of disease, 
including sepsis, shock, gangrene, deafness, seizures, CNS damage, or limb amputation, 
taken together support vaccination as the best approach for preventing the most 
epidemiologically and clinically important forms of bacterial meningitis.  
While the brain and meninges are relatively anatomically inaccessible, once breached by a 
pathogen the blood-brain barrier tends to become more permeable to medicines because of 
resultant inflammation. Haemophilus influenzae type b, the meningococcus and the 
pneumococcus are generally highly sensitive to antibiotics, although resistance has been 
increasingly reported with pneumococci and a few meningococcal strains, leading to 
recommendations for the empiric use of third-generation cephalosporins. Therapies are also 
available for other forms of meningitis. Corticosteroids may be recommended as adjunctive 
therapy to reduce some symptoms (36-37). 
3. Prevention of meningitis 
Strategies and policies to prevent and control meningitis tend to involve narrow, categorical, 
pathogen-specific programs. Few if any broad policies spanning the gamut of pathogens 
responsible for causing meningitis exist. This shortcoming reflects the differences in the 
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epidemiology of the etiologic agents, the limited antigenic composition and coverage of the 
available vaccines, the complexity of primary prevention and secondary prevention 
modalities, and the cost and complexity of instituting large scale programs.  
In epidemic situations, antibiotics may be used to prevent bacterial meningitis in close 
contacts or communities within a reasonable period (1 week in the case of meningococcal 
meningitis) from the diagnosis of an index case. Current recommendations often call for 
third-generation cephalosporins to address possible drug-resistant strains. (22-23, 36-37). In 
addition, intrapartum antibiotics are routinely administered to mothers colonized with 
Group B streptococcus to prevent infant disease. Nevertheless, vaccination remains the most 
effective means of preventing both the most common causes of bacterial meningitis and 
some viral pathogens, like measles and mumps. Although vaccines have been licensed 
steadily throughout the late twentieth and early twenty-first centuries for encapsulated 
bacteria, areas for improvement remain.  
Investigation into vaccines that limit meningitis followed work against other deadly 
diseases such as rabies, yellow fever, and smallpox. The diphtheria and tetanus toxoid 
vaccines originally designed in the 1920s were later adapted to act as protein carriers in 
the current polysaccharide-protein conjugate vaccines. Another early twentieth-century 
vaccine to prevent a range of illnesses, including meningitis, was the Bacille Calmette-
Guérin (BCG) vaccine against tuberculosis, which has become the most widely used 
vaccine in the WHO Expanded Programme for Immunisation. Measles and mumps 
vaccines were developed during the second half of the twentieth century, and, like 
diphtheria and tetanus vaccines, remain an essential part of early childhood universal 
vaccination programs (40).  
The first vaccines against encapsulated bacterial meningitis-causing pathogens during the 
1960s and 1970s employed the purified outer polysaccharide capsule to provide immune 
responses in persons over 2 years of age who were able to mount B-cell responses. Such 
vaccines have been used successfully in situations where individual protection is needed for 
a limited amount of time. However, these vaccines may have blunted or diminished 
responses with repeat dosing, possibly due to B-cell depletion and do not offer protection in 
infants and others who cannot mount B-cell responses. The next generation of conjugated 
pneumococcal, meningococcal and Haemophilus influenzae type b  vaccines offer protection to 
infants and young children and allow for booster responses with repeat dosing. Extensive 
vaccination of infants and young children with pneumococcal vaccines has led to 
considerable reductions in disease in non-target age groups by means of herd protection, 
which was also evident in meningococcal serogroup C vaccine programs that include the 
primary carriage population (1, 2, 40-41).  
Policy makers and health care providers generally consider the full spectrum of clinical disease 
caused by meningitis-causing pathogens when making decisions about therapy, prevention, or 
vaccination. For example, meningococci can cause a range of clinical syndromes including 
septicemia, bacteremia, and localized suppurative infections such as arthritis. Similarly, 
pneumococci cause otitis media and pneumonia, which create serious public health 
consequences. Further, Haemophilus influenzae type b  vaccine policy was strongly affected by 
the possibility to prevent pneumonia and epiglottitis, which is very difficult to manage. 
Meningococcal vaccine policy must also address the possibility for unpredictable, severe  
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VACCINE 
PRIMARY DISEASE 
TARGETED 
CURRENT ROUTINE USE EXAMPLES 
Early Twentieth Century   
Bacille-Calmette-Guérin 
(BCG) Vaccine 
Tuberculosis WHO countries 
Mid-Twentieth Century   
Measles virus vaccine Measles Infants and toddlers 
Mumps virus vaccine Mumps Infants and toddlers 
Late twentieth Century   
Meningococcal 
polysaccharide vaccines 
Meningitis and 
septicemia 
Hajj travel in countries without 
access to conjugate vaccines 
Pneumococcal 
polysaccharide vaccine 
Meningitis and 
pneumonia 
Elderly persons in countries without 
conjugate vaccines against all 
significant serotypes 
Haemophilus influenzae 
type b  conjugate vaccine 
Meningitis and 
epiglotitis 
Infants and toddlers 
Pneumococcal conjugate 
vaccine 
Meningitis, 
pneumonia and otitis 
media 
Infants and toddlers 
Meningococcal conjugate 
vaccines 
Meningitis and 
septicemia 
Infants, toddlers, adolescents, 
travelers, Hajj pilgrims 
Note: vaccines against Japanese and tick-borne encephalitis also became available during the twentieth 
century. (1,2, 5, 40-41) 
Table 6. Vaccines against pathogens that cause meningitis 
outbreaks and epidemics that may prevent adequate distribution of antibiotics fast enough 
to treat individuals and to curtail the spread of infection through a community. The 
possibility of drug resistance can also impact vaccine policy and treatment decisions (2). 
3.1 Haemophilus influenza type b vaccines 
No single intervention has done more to prevent cases of bacterial meningitis than the 
successful introduction of conjugate Haemophilus influenzae type b  vaccines, which stands as 
a major triumph in the history of vaccinology (42-43). The virulence of Haemophilus 
influenzae type b  results from its unique polyribosylribitol phosphate (PRP) capsule, which 
is thought to be particularly effective at enabling the organism to evade complement-
mediated lysis and avoid splenic clearance (44-45). Previous to the development of 
conjugate vaccines, Haemophilus influenzae type b  was the most common cause of bacterial 
meningitis, and disease incidence remains high in countries that do not immunize infants 
(42-43). Haemophilus influenzae type b meningitis occurs primarily in older infants and 
toddlers, during a “window of vulnerability” corresponding to a gap in anti-capsular 
antibody titers that occurs between a decline in maternal antibody and the second year of 
life. Conjugated Haemophilus influenzae type b  PRP (or PRP derivative) vaccines enabled the  
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Vaccine Diseases/pathogens covered Regions used 
Haemophilus influenzae type b (Hib) conjugate vaccines
PRP-T 
PRP-OMPC 
PRP-D 
PRP-CRM197 
Haemophilus influenzae type b  
North America and 
Europe 
Haemophilus influenzae type b  and pertussis-containing vaccine combinations
DTaP-IPV/Hib 
Diphtheria, tetanus, pertussis, 
polio, Haemophilus influenzae 
type b 
North America 
DTaP-IPV/Hib-HBV 
Diphtheria, tetanus, pertussis, 
polio, Haemophilus influenzae 
type b , hepatitis B
Europe 
DTP-Hib 
Diphtheria, tetanus, pertussis, 
Haemophilus influenzae type b  
Africa, Asia, Latin 
America 
DTP-Hib-HBV 
Diphtheria, tetanus, pertussis, 
Haemophilus influenzae type b , 
hepatitis B 
Africa, Asia, Latin 
America 
Haemophilus influenzae type b  meningitis combinations
MenCY-Hib 
Meningococcal serogroups C 
and Y, Haemophilus influenzae 
type b  
Not yet in use 
MenC-Hib 
Meningococcal serogroup C, 
Haemophilus influenzae type b 
UK 
Other Haemophilus influenzae type b  combinations
Hib-HBV 
Haemophilus influenzae type b  
and hepatitis B 
North America 
Europe 
-aP: acellular pertussis; CRM197: cross-reacting material; D: diphtheria toxoid; HBV: hepatitis B virus; 
IPV: inactivated poliovirus vaccine; MenC meningococcal serogroup C; MenCY: meningococcal 
serogroups C and Y; OMPC: outer membrane protein complex; P: whole-cell pertussis; PRP: 
polyribosylribitol phosphate; T: tetanus toxoid.  (40-52) 
Table 7. Examples of vaccines against Haemophilus influenzae type b  
institution of immunization policies shaped by an understanding of epidemiology. Universal 
use of Haemophilus influenzae type b conjugate vaccines in the first year of life provided 
protection from invasive disease, reductions in carriage, and herd effects, an approach that 
was tailored to fit existing routine infant immunization schedules. Combining conjugate 
Haemophilus influenzae type b  vaccine with other routine infant vaccines has allowed for ease 
of implementation in increasingly crowded immunization schedules (42-52). 
3.1.1 Pneumococcal vaccines 
The pneumococcus comprises antigenically distinct types based on the chemistry of the 
polysaccharide outer capsule. Vaccines have therefore been designed to provide protection 
against the broadest number of serotypes in a specific population (Table 8).  
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Pneumococcal 
Types 
23-valent 
polysaccharide 
vaccine 
7-valent 
CRM-conjugate
vaccine  
10-valent protein 
D-conjugate 
13-valent CRM-
conjugate 
vaccine 
Target age group Adults Infants Infants infants 
1 X X X
2 X
3 X X
4 X X X X
5 X X X
6A X
6B X X X X
7F X X X
8 X
9N X
9V X X X X
10A X
11A X
12F X
14 X X X X
15B X
17F X
18C X X X X
19F X X X X
19A X X
20 X
22F X
23F X X X X
33F X
CRM: cross reacting material 197; protein D is derived from nontypeable Haemophilus influenzae  
(40, 63) 
Table 8. Pneumococcal types covered by available polysaccharide vaccines for use in adults 
and polysaccharide-protein conjugate vaccine for use in infants and young children 
The UK has been a leader in implementing universal infant vaccination against bacterial 
meningitides. Awareness raised by charities such as the Meningitis Research Foundation or 
the Meningitis Trust and the media helped support the inclusion of pneumococcal vaccines 
in not only routine infant schedules but also into at-risk programs. At-risk programs may 
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have little impact on disease burden (54), particularly given that immunization of infants 
and young children provides some protection in older age groups by virtue of herd 
protection (55). Pneumococcal conjugate vaccine also provided unexpected benefits such as 
the prevention of secondary bacterial super-infection in influenza (56). 
The 7-valent pneumococcal conjugate vaccine has been in use in the US since 2000 with 
subsequent licensing in the EU and elsewhere. Although the initial European 
recommendation was for at-risk groups, by 2006 more countries were making universal 
recommendations and providing funding. Cost-effectiveness data from the US, some 
European countries and Australia (57) have been reported and indicate that vaccination can 
be cost-saving, as in Germany, partly as a result of reduction of high-incidence but also 
lower severity infections such as otitis media. Favorable pharmacoeconomic results tend to 
drive routine (universal use) policy implementation. Pneumococcal conjugate vaccine is 
funded in many countries including Turkey, Mexico, and South Africa, and in some GAVI-
eligible countries.  
The safety, efficacy and effectiveness of the 7-valent pneumococcal conjugate vaccine were 
established through pivotal trials, long-term surveillance, and monitoring. In a multi-centre 
study of 1379 pneumococcal meningitis cases in the US from 1998 to 2005 (58), incidence 
declined from 1.13 to 0.79 cases per 100,000 persons, a 30.1% reduction (P<0.001). 
Reductions were most marked in those less than 2 years and more than 65 years of age, 
respectively 64.0% and 54.0% (P<0.001). Non-vaccine serotypes were noted to cause more 
disease after the introduction of vaccine. Newer 10- and 13-valent pneumococcal vaccines 
have been studied in clinical trials and are appearing in some markets. A 15-valent 
pneumococcal conjugate vaccine is also in clinical trials. 
Questions regarding the efficacy of 23-valent pneumococcal polysaccharide vaccine have led 
the UK to consider eliminating its routine use in the elderly and confining use to specific at-
risk groups (59). Licensing of the 13-valent pneumococcal conjugate vaccine for adults 
should provide an alternative. In France, the 13-valent pneumococcal vaccine, which is 
already licensed for use in children, may reduce disease where serotypes 7F and 19A have 
come to predominate (60) while in the African meningitis belt there is potential for the 
reduction in the burden of disease through coverage of serotype 1 (61). 
3.2 Meningococcal vaccines 
The epidemiology of meningococcal disease is characterized by dynamic shifts in serogroup 
incidence over time and across geography. In addition, hypervirulent strains cause 
unpredictable outbreaks, and epidemics are reported annually in the sub-Saharan 
meningitis belt. Six meningococcal serogroups, A, B, C, W-135, X, and Y cause the majority 
of disease worldwide and are considered epidemiologically important by the WHO (1, 5, 9). 
Currently, conjugate vaccines are available against serogroups A, C, W-135 and Y. Routine 
immunization with the serogroup C conjugate vaccines dramatically reduced disease 
incidence and asymptomatic carriage, thus leading to herd protection in many countries 
including the UK, Ireland, the Netherlands, and Canada. Effective vaccination policy 
mandated immunization of both infants and adolescents, an important reservoir for 
meningococcal carriage. These findings have yet to be replicated with additional serogroups 
(1, 9). Quadrivalent meningococcal vaccines against serogroups A, C, W-135 and Y are 
routinely recommended in North America for use in adolescents, and a booster dose is 
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recommended in the US. Additional recommendations for meningococcal vaccination 
include the military, persons travelling to regions with endemic or epidemic disease, and 
those attending the annual Hajj pilgrimage to Mecca (1, 25, 62). A very significant new 
advance in this field is the recent implementation of serogroup A conjugate vaccine in the 
African meningitis belt (8). 
 
 
Fig. 2. Micrograph at 1150 X magnification of meningococci. Image by Dr Brodsky c. 1966. 
Centers for Disease Control and Prevention Public Health Image Library ID #6423 (15). 
Serogroup B presents special challenges because its capsular polysaccharide is non-
immunogenic, resulting in the need for subcapsular antigenic approaches (1, 11). Serogroup B 
vaccines using outer membrane vesicles (OMVs) as the primary antigen have been used to 
control specific clonal outbreaks in Cuba, Chile, Brazil, New Zealand, France and Norway. 
Various other subcapsular antigens have been investigated (10-11). A genomic method known 
as reverse vaccinology led to the development of 4CMenB, which is the only vaccine that has 
been shown to generate antibody responses against genetically heterologous serogroup B 
strains in Phase 3 trials in both infants and adolescents  and has been submitted for approval 
to the European Medicines Agency. 4CMenB is a multicomponent vaccine that combines 
factor H binding protein, Neisserial adhesin A, and Neisseria heparin binding antigen with 
OMV from the New Zealand outbreak strain. The vaccine promises to be an important 
advance in vaccine practice (11, 63-65). Other serogroup B vaccines are under development. 
An optimal strategy for meningococcal disease control would include broad-coverage 
vaccines in infants where the disease incidence is highest coupled with immunization of 
adolescents (where peak carriage occurs) to induce herd effects and prevent secondary peak 
disease. Vaccine availability, implementation issues and cost have driven meningococcal 
vaccine policies, which tend to be narrow in scope (65). 
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4. Policy decisions for the prevention of meningitis 
Strategies and policies to prevent and control meningitis tend to be pathogen-specific, 
because differences in epidemiology, available vaccines, cost and the complexity of 
instituting large scale programs would make general guidelines unhelpful. Nevertheless, 
the vision of a meningitis free world is most likely to be realized from innovative 
approaches to integrated meningitis prevention and control. 
Implementation of vaccines against meningitis-causing organisms has been a major priority 
of global health funding organizations such as the Gates Foundation and the Global Alliance 
for Vaccines and Immunisation (GAVI). The Gates Foundation alone has committed more 
than 14 billion dollars toward vaccines for developing countries (66). Investments such as 
these have led to innovative strategies and partnerships toward vaccines against meningitis. 
Early efforts focused on introducing existing vaccines, such as Haemophilus influenzae type b 
and pneumococcal conjugate vaccines, to developing countries, while more recent efforts 
include the development of specialized low-cost vaccines targeted to the needs of 
developing nations. 
A notable GAVI initiative was the introduction of Haemophilus influenzae type b  vaccine to 
the world’s poorest countries, which began in 2005, on the heels of the WHO global 
Haemophilus influenzae type b  vaccine recommendation. By 2008, half of eligible countries, 
representing 42% of eligible infants, had access to free or subsidized vaccine (67). GAVI has 
also funded 7-valent pneumococcal vaccine, which has been adopted by a number of 
countries, the first being Rwanda (68). The Meningitis Vaccine Project recently supported 
the development of a low-cost (40 cents a dose) tetanus toxoid conjugate vaccine against 
serogroup A meningococcal disease for use in the meningitis belt. This project was an 
innovative multi-stakeholder partnership including the WHO, UNICEF, the US Centers for 
Disease Control, the US Center for Biologics Evaluation and Research (CBER), and the 
Serum Institute of India. This vaccine has dramatically reduced disease and associated 
morbidity and mortality after immunization of 19 million residents of Burkina Faso, Mali 
and Niger in the course of a few weeks (8, 68).  
4.1 Considerations for the design of preventative interventions 
Vaccine policy for meningitis, as for most infectious diseases, is determined by the burden of 
disease, public awareness of the problem, availability of vaccines and the ability to fund 
vaccination campaigns. Yet even with compelling disease burden, clear epidemiologic 
justification and ample funding, difficulties in vaccine formulation or adding vaccines to 
crowded schedules may present significant barriers to implementing vaccine policies. The 
prevention of bacterial meningitis requires vaccinating a large proportion of the community 
and immunization against relatively rare diseases, thus such programs might not meet 
pharmacoeconomic parameters in all nations as it did recently in the African meningitis  
belt (69). 
Routine immunization implementation may be necessary to assess clinical effectiveness, cost 
effectiveness and herd effects; therefore, effective vaccine policies must consider multiple 
variables in the use of health care resources. The perceived and actual burden of disease 
may vary because public perception can be skewed by reports of epidemics or small 
numbers of cases of severe disease. Or, the true burden of disease may be masked by  
www.intechopen.com
 
Strategies for the Prevention of Meningitis 175 
Epidemiology 
Populations suffering from disease 
Populations carrying or transmitting the causative organism 
Genetic, group, and strain diversity of the organism 
Genetic, strain, or serogroup shifts over time and space 
Escape mutants 
Serogroup or serotype replacement over time and as a result of vaccination campaigns 
Proximity of populations (potential for herd effects) 
Vaccines 
Number and type of available vaccines 
Ability for vaccines to protect against circulating pathogens in a given region 
Effects on immunogenicity and efficacy when given with existing vaccine schedules 
Duration of immunity 
Effects in target age groups 
Policy  
Existing vaccine schedules 
Timing of doses 
Need for booster doses or catch-up campaigns 
Funding 
Ability to reach key populations to administer vaccines 
Possibility for herd effects 
Reduction of the risk for developing antibiotic resistance 
Table 9. Considerations for developing vaccine policy 
under-diagnosis, under-reporting or, if early antibiotic treatment prevents case confirmation 
by culture (70-71). Thus, public awareness of disease burden should precede explanations of 
new vaccines. Media reports may occasionally be counter-productive, especially when 
considering their treatment of vaccine safety (72).  
Vaccine availability can be limited by logistical factors like the lack of a universally 
protective antigen. Thus, not all meningitides are vaccine-preventable in practice (e.g. 
serogroup B meningococcus, group B streptococcus), nor are many of the encephalitides. 
Vaccines cannot be considered available unless they have been approved for licensure, yet 
licensure is necessary but not sufficient for availability to the general public because funding 
sources have a strong impact on policy decisions. In the public market, pharmacoeconomic 
considerations may appear calculating or callous to the general public. In a “private” 
market, the vaccinee must willingly obtain and pay for the vaccine. Although in this context, 
the decision to receive vaccine is less likely to be driven by a sense of public-mindedness, 
the near-universal uptake of pneumococcal conjugate vaccine in Portugal indicates that 
collective responsibility may be powerful in some regions. 
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4.2 Policy approaches to vaccine against meningitis-causing pathogens 
Universal (age-based) routine immunization is a primary model for limiting or eliminating 
meningitis globally. Prevention in the context of disease outbreaks involves antibiotic 
chemoprophylaxis as well as targeted vaccine use, generally in the setting of meningococcal 
disease. Universal vaccination approaches require multiple considerations because 
successful prevention arises only from a clear understanding of several key factors including 
the populations at greatest risk of disease, the population where carriage occurs, the features 
of available vaccines, the feasibility of implementation of immunization policies (Figure 3). 
Risk groups
Policies for 
prevention
Clinical 
practice
Public 
health 
practice
Organism, 
molecular 
microbiology, 
evolution
Epidemiology
Vaccines
Conjugate technology
Vaccine safety and 
efficacy
Antibiotics
Diagnostic 
methods
Polysaccharide
Prognosis
Sporadic disease
Epidemics
Cost:benefit
Genomics
Carriage
Public awareness
Infrastructure
 
Fig. 3. Considerations that inform policymaking decisions for meningitis prevention 
Universal immunization against Haemophilus influenzae type b , meningococcal serogroup C 
and pneumococcal disease stand as exceptionally noteworthy successes in the primary 
prevention of meningitis. These universal policies are more likely to protect high-risk 
individuals than selective programs in part because risk factors may be poorly understood. 
Debates about selective versus universal or voluntary and compulsory vaccination policies 
remain unresolved.  
Primary prevention of other causes of meningitis is somewhat more complex. Control of 
meningococcal serogroup C resulted through the expansion of the immunization schedule 
to include older children and adolescents, reducing carriage to provide adequate herd 
effects and the use of catch-up campaigns to ensure vaccine coverage.  
Secondary prevention of meningitis can include interventions, like antibiotic 
chemoprophylaxis, that can operate at the population level or for an individual. Targeted 
use of vaccines within communities or geographic areas can also control epidemic as shown  
 
www.intechopen.com
 
Strategies for the Prevention of Meningitis 177 
Young children were at the highest risk of disease and also comprised the primary 
population where carriage occurs  
Glycoconjugate vaccines enabled direct protection and reduction in carriage that 
provided further herd effects in the critical at-risk population simultaneously 
Implementation of immunization was straightforward because vaccines fit well into the 
existing routine infant immunization schedules 
Herd effects extended beyond the vaccinated population and into the general 
population because primary vaccination reduced carriage in the key reservoir for the 
causative disease pathogens. 
Table 10. Considerations that led to the success of universal vaccination policies against 
Haemophilus influenzae type b and pneumococcal diseases 
in Cuba, Norway and New Zealand by the use of tailor-made outer membrane vesicle 
vaccines against meningococcal serogroup B (73). Policy focus in the Middle East has been 
directed toward the control of meningococcal disease Hajj pilgrims (62, 74). Globally, 
routine infant immunization schedules commonly include Haemophilus influenzae type b  and 
pneumococcal conjugate vaccines within the first six months of life, with a booster in the 
second year of life, which is important to long-term protection. Meningococcal vaccine 
schedules are more variable and routine recommendations may target infants, older 
children, adolescents, or some combination of these.  
4.3 Expert commentary and five year view 
Where meningitis prevention and control is concerned, optimally, vaccine innovation will 
involve the development of broadly protective vaccines that are safe and immunogenic 
across the age spectrum. From a pure feasibility point of view, combining antigens will be 
critically important given the increasingly crowded immunization schedules. Cost and the 
crowded immunization schedules are typically cited as the major impediments to making 
progress in the area of meningitis prevention and control.  
The recent advent of vaccines to prevent meningitis and sepsis caused by Haemophilus 
influenzae type b, the pneumococcus and the meningococcus further completes a general 
picture of universal vaccination to promote public health, beginning with vaccine policies 
against diseases like measles, mumps, polio, and diphtheria. Yet most of the world’s 
children remain unprotected, which underscores the work of organizations like the WHO, 
the Gates Foundation and GAVI in limiting infectious disease. 
The effects of vaccine programs depend on many factors. Antibody concentration wanes 
rapidly in infants, and more slowly in toddlers and young children while persons 10 years 
of age and older can have antibody persistence for five years or more (75). Herd protection 
may depend on booster dosing in various age groups or catch-up campaigns. Similarly, 
continued vaccination of infants may be necessary to protect the vulnerable elderly 
population from pneumococcal disease. Yet, with the dramatic reduction of cases, the 
political will to support booster vaccinations may be lacking.  
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Compliance, and therefore vaccine coverage, may be an issue for adolescents, who 
traditionally visit medical practitioners infrequently, and who often refuse vaccines but 
represent an important population for meningococcal carriage and also have an increased 
risk for case fatality. Combined vaccination with other routine vaccinations for this age 
group, such as Tdap and HPV, may help overcome this difficulty, and are supported by 
clinical studies (22-23, 76-78). Booster immunizations with DT/IPV/aP combinations, catch-
up for MMR/V and depending on the country, catch-up vaccination for hepatitis A or for 
hepatitis B may provide additional opportunities for vaccination of adolescents. Suboptimal 
coverage rates, especially for newer vaccines, place substantial numbers of adolescents at 
risk. One approach to increase adolescent vaccination is to establish routine school-based 
adolescent immunization programs by primary care trusts, school nursing teams and 
similar facilities.  
In a recent survey analyzed by the Federal Center for Health Education (Bundeszentrale für 
gesundheitliche Aufklärung) in Germany, 64% of parents had a positive opinion on 
vaccination, 35% declined individual vaccines due to various reservations and only 1% 
generally dismissed vaccines. About 50% of the parents with reservations reported that the 
reason for their reservation was that they assessed the vaccine to be unnecessary, 
vaccination was discouraged by the physician (41%) or they were afraid of side reactions 
(40%). The survey data reveal the central role of the medical profession (79).  
Education of adolescents, their parents and/or guardians, health care providers, policy 
makers and physicians is vital to successful implementation of adolescent immunizations 
and it has to be considered that the role of pediatricians gradually decreases for adolescents 
older than 14 years, while the role of the family practitioner, internist, and gynecologist 
increases. Of note, 35% of the preventive care visits made by late adolescent females (18-21 
years old) are to obstetricians and gynecologists, which provides an opportunity for 
concomitant HPV and quadrivalent meningococcal vaccines. Obstetricians may be 
particularly well positioned to intervene in meningitis affecting the very young infant in the 
future by administering vaccines to pregnant women to limit infections such as Group B 
streptococcus, a leading cause of neonatal meningitis. For various reasons, family 
practitioners are often slower than pediatricians to accept new universal vaccine 
recommendations (80-81), which might require adjustments in communication about new 
products. 
Achieving reductions in meningitis has to remain a top priority for the modern world. 
Within this context, a vaccine with the following properties might be considered a magic 
bullet were it to be developed:  
 Multicomponent vaccine with coverage against Haemophilus influenzae type b, and PCV 
(23 - valent), and meningococcus (5 valent: A, B, C, W-135, and Y) 
 Safe, immunogenic, and effective in young infants, children, adolescents and adults 
 Ability to reduce or eliminate carriage 
Such a vaccine, if used appropriately, could help bring us closer to a “meningitis free 
world”. Although a singular such vaccine is not likely to be developed within the next five 
years, incremental progress is inching us closer toward such broad vaccines. Admittedly, 
Group B streptococcus remains a critical target, and the new paradigm of maternal 
immunization will be required for successful control of that disease. Moreover, listerial, 
www.intechopen.com
 
Strategies for the Prevention of Meningitis 179 
viral, fungal, mycobacterial and other rare forms of meningitis will remain with us for some 
time to come albeit at low rates. The world is now positioned with an ever growing 
armamentarium of preventative tools the likes of which physicians and public health 
officials of past generations could only have dreamed. 
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